Fusion Antibodies (FAB)

Company name:Fusion Antibodies Plc
EPIC:FABTrading Currency:GBX
Market Sector:AMQ1ISIN:GB00BDQZGK16
Market Segment:ASQ1Share Type:DE
WWW Address:http://www.fusionantibodies.com/Description:ORD 4P
 Price Price Change [%] Bid Ask Open High Low Volume
 55.50 images.advfn.com/imagesnew/2/us/dot 0.0 [0.00] 53.00 58.00 - - - -
 Market Cap. [m] Shares In Issue [m] Beta EPS DPS PE Ratio Yield 52-Wks-Range
 14.41 25.96 -0.00 -11.40 - - - 142.50 - 55.50

Fusion Antibodies Key Figures

Key Figures
(at previous day's close)
Market Cap.14.41m
Shares In Issue25.96m
Prev. Close55.50
PE Ratio- 
Dividend Yield-%
EPS - basic-11.40p
Dividend PS-p
Dividend Cover- 
Cash Flow PS-4.38p
Return On Equity (ROE)-61.07%
Operating Margin-30.35%
PEG Factor- 
EPS Growth Rate-256.25%
Dividends PS Growth Rate-%
Net Debt-1.60m
Gross Gearing18.58%
Quick Assets4.23m
Net Working Capital3.71m
Intangibles / Fixed Assets0.18%
Turnover PS16.04p
Pre-Tax Profit PS-4.87p
Retained Profit PS-11.17p
Cash PS10.35p
Net Cash PS6.51p
Net Tangible Asset Value PS *18.28p
Net Asset Value PS18.28p
Spread5.00 (8.62%) 

Fusion Antibodies Balance Sheet

%1$s Balance Sheet

Share Price Performance

Share Price Performance
Sample Period HighLow
1 week57.5055.50
4 weeks67.5055.50
12 weeks73.5055.50
1 year142.5055.50

Share Price Chart (5 years)

Share Price Chart (5 years)

Fusion Antibodies Historic Returns

%1$s Historic Returns
Giorni da oggi OpenChange%Open Avg.Avg. Daily Vol [m]Total Vol [m]VWAP
1 week57.50-2.00-3.4855.500.0255.65
4 weeks66.00-10.50-15.9155.500.0159.67
12 weeks73.50-18.00-24.4955.500.0263.20
26 weeks122.50-67.00-54.6955.500.0281.90
1 year134.00-78.50-58.5855.500.02103.68
3 years54.501.001.8353.500.04130.21
5 years83.50-28.00-33.5324.500.03128.35

Fusion Antibodies Key Management Ratios


Fusion Antibodies Investment Ratios

%1$s Investment Ratios
(Market value analysis) at previous day's close
PQ Ratio- 
PE Ratio- 
Tobin's Q Ratio 2.43 
Tobin's Q Ratio (excl. intangibles)2.43 
Dividend Yield-%
Market-to-Book Ratio3.04 
Price-to-Pre-Tax Profit PS-11.40 
Price-to-Retained Profit PS-4.97 
Price-to-Cash Flow PS-12.68 
Price-to-Sales PS3.46 
Price-to-Net Tangible Asset Value PS3.04 
Price-to-Cash PS5.36 
Net Working Capital PS14.29 
Price Pct to Working Capital PS3.89%
Earnings Yield-%
Average PE- 
Years in average- 
PE to PE average-%

Fusion Antibodies Financial Ratios

%1$s Financial Ratios
(Leverage Ratios)
Debt Ratio1.80%
Debt-to-Equity Ratio0.02 
Debt-to-Equity Ratio (excl. Intgbl)0.02 
Debt-to-Equity Market Value0.01 
Net Gearing-27.50%
Net Gearing (excl. Intangibles)-27.51%
Gross Gearing18.58%
Gross Gearing (excl. Intangibles)18.58%
Gearing Under 1 Year17.08%
Gearing Under 1 Year (excl. Intgbl)17.09%
(Liquidity Ratios)
Net Working Capital to Total Assets63.62%
Current Ratio4.72 
Quick Ratio (Acid Test)4.24 
Liquidity Ratio2.70 
Cash & Equiv/Current Assets57.09%
(Solvency Ratios)
Enterprise Value11.81m
CFO/Attributable Profit- 
Total Debt/Equity Market Value0.08 
Total Debt/Sales0.26 
Total Debt/Pre-Tax Profit-0.86 
Total Debt1.08m
Total Debt/Net Current Assets0.29%
(Dodds - Graham Ratios)
3 yr Compound Earnings Growth-%
5 yr Compound Earnings Growth-%
10 yr Compound Earnings Growth-%
Earn drops > 5% in 10yrs2 
Beta coefficients
Beta (60-Mnth)Beta (36-Mnth)

Fusion Antibodies Operating Ratios

%1$s Operating Ratios
(Profitability Ratios)
Return On Capital Employed (ROCE)-26.15%
Return On Assets (ROA)-48.85%
Net Profit Margin-69.60%
Assets Turnover0.70 
Return On Equity (ROE)-61.07%
Return On Investment (ROI)-58.65%
Dividend Payout Ratio-%
Plowback Ratio100.00%
Growth from Plowback Ratio-%
Net Income Of Revenues-69.60%
(Asset Utilisation Multiples)
Shareholders Equity Turnover0.87 
Fixed Assets Turnover3.21 
Current Assets Turnover0.90 
Net Working Capital Turnover 
Inventory Turnover10.16 
(Other Operating Ratios)
Total Assets-to-Sales1.42 
Debt Collection Period185.26Days

Fusion Antibodies Dividends

Sorry No Data Available

Fusion Antibodies Fundamentals

Profit and Loss Account
 31 Mar 2018 (GBP)31 Mar 2019 (GBP)31 Mar 2020 (GBP)31 Mar 2021 (GBP)
pre tax profit-0.71-26.44%-1.50-68.74%-1.07-27.55%-1.26-30.35%m
attributable profit-0.70-26.01%-1.26-57.95%-0.70-17.89%-2.90-69.60%m
retained profit-0.70-26.01%-1.26-57.95%-0.70-17.89%-2.90-69.60%m
eps - basic (p)-4.30 -5.70 -3.20 -11.40 
eps - diluted (p)-4.30 -5.70 -3.20 -11.40 
dividends per share- - - - 

Fusion Antibodies Balance Sheet

Balance Sheet
 31 Mar 2018 (GBP)31 Mar 2019 (GBP)31 Mar 2020 (GBP)31 Mar 2021 (GBP)
 31 Mar 2018 (GBP)31 Mar 2019 (GBP)31 Mar 2020 (GBP)31 Mar 2021 (GBP)
fixed assets fixed assets0.557.58%1.5925.44%1.4724.34%1.1219.26%m
intangibles intangibles--%0.010.10%0.000.07%0.000.03%m
fixed investments fixed investments--%--%--%--%m
current assets - other current assets - other--%--%--%--%m
stocks stocks0.081.13%0.243.89%0.345.63%0.488.23%m
debtors debtors2.0928.98%2.4238.79%2.6944.52%1.5426.40%m
cash & securities cash & securities4.4962.30%1.9831.79%1.5425.45%2.6946.07%m
creditors - short creditors - short0.577.91%0.8012.75%0.9916.37%1.0017.08%m
creditors - long creditors - long0.060.88%0.091.48%0.243.96%0.091.49%m
creditors - other creditors - other--%--%--%--%m
subordinated loans subordinated loans--%--%--%--%m
insurance funds insurance funds--%--%--%--%m
ord cap, reserves ord cap, reserves6.5891.21%5.3585.77%4.8179.67%4.7581.42%m
prefs, minorities prefs, minorities--%--%--%--%m
NAV Basic- - - - 
NAV Diluted- - - - 

Fusion Antibodies Cash Flow Statement

%1$s Cash Flow Statement
31 Mar 2018 (GBP)31 Mar 2019 (GBP)31 Mar 2020 (GBP)31 Mar 2021 (GBP)
Operating CF0.08-1.10-0.16-1.14m
Pre-Financing CF-0.37-2.48-0.26-1.50m
Retained CF4.21-2.51-0.451.15m

Fusion Antibodies Brokers

%1$s Brokers
Fairfax I.S. PLCMarket Maker(MMF)Broker/DealerFFAXFRFXGB21001
Shore Capital Stockbrokers LtdMarket Maker(MMF)Broker/DealerSCAPSHOCGB21
Winterflood Securities LtdMarket Maker(MMF)Broker/DealerWINSWNTSGB2LBIC

Your Recent History
Fusion Ant..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.